Abstract: The present invention relates to the use of zinc and copper gluconate in the treatment of methicillin-resistant Staphylococcus aureus and dietary supplements for mammals comprising zinc and copper gluconate and their use in treatment of methicillin-resistant Staphylococcus aureus.

Abstract: Sunscreen compositions, products and methods that include at least one UVA sunscreen active agent, at least one UVB sunscreen active agent, and one or more water insoluble film forming polymers. The compositions, products and methods may further include one or more active or inactive cosmetic ingredients. The water insoluble film forming polymers synergistically affect the UVA and UVB sunscreen active agents, in particularly the UVA sunscreen active agents by significantly enhancing the water resistance of the UVA sunscreen active agents after water exposure as determined by the SPF and UVAPF values measured before and after water exposure.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.

Abstract: A pharmaceutical composition useful for preventing and treating retinal neurodegeneration related diseases comprising chromium chloride and magnesium sulfate, thickening agent, penetration enhancer, and pharmaceutical acceptable carrier, diluent or excipient. Further disclosed is a method for treating and preventing retinal neurodegeneration related diseases utilizing the composition.

Abstract: A microcapsule composition useful in delivering an active material contains a first microcapsule and a second microcapsule. The first microcapsule has a zeta potential of 10 mV or greater, the second microcapsule has a zeta potential of 5 mV or less, and the weight ratio of the first microcapsule and the second microcapsule is between 1:10 and 10:1. Also disclosed are consumer products containing such a microcapsule composition.

Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.

Abstract: A moisturizing composition and an application thereof in the preparation of a moisturizing cosmetic product; each component in the formulation cooperates with the others to jointly provide the effects of increasing the moisture content of the skin and reducing the loss of moisture of the skin; compared with the efficiency of using a single component or several components alone, the efficiency of the present invention is significantly increased, indicating that compounding each component at a proper ratio produces a synergistic effect, thereby improving moisturizing efficiency.

Abstract: The present invention relates to a serum LDL cholesterol lowering edible product containing plant sterol ester and/or plant stanol ester, and especially to a dietary supplement product.

Abstract: Disclosed are compositions and methods for their use that include a combination of Leontopodium alpinum extract, Halidrys siliquosa extract, vegetable amino acids, niacinamide, hexylresorcinol, Pinus pinaster extract, Betula alba extract, Albizia julibrissin bark extract, hydrolyzed Candida saitoana extract, Lentinus edodes mycelium extract, and/or Opuntia tuna fruit extract.

Abstract: The present invention concerns a composition comprising micro particles of polyinosinic-polycytidylic acid (Poly (I:C)) and a carrier polymer selected from starch, alginate, blanose or DPPC (dipalmitoylphosphatidylcholine) for use in preventing and/or treating viral infections of the upper respiratory tract or the common cold and a device, preferably a nasal delivery system, comprising said composition for use by a patient in need to prevent and/or treat infections or the common cold.

Abstract: A nutritional supplement having a combination of minerals and chelated nutrients is provided that offers therapeutic benefits to individuals having thyroid regulation conditions. The formulation is also beneficial for other medical conditions associated with polar uptake of vitamins and nutrients within the digestive system of individuals, including, but not limited to individuals suffering from auto-immune diseases.

Abstract: Provided are antimicrobial compositions that include a hydrogen peroxide generator, a peracid catalyst, a sugar acid lactone selected from among a gluconolactone, a galactonolactone, a mannonolactone, a gulonolactone and a combination thereof in an amount from about 10 wt % to about 60 wt %, an acetate, and a carboxylic acid, where the ratio between the hydrogen peroxide generator and the peracetic acid catalyst is from about 1.5:1 to about 3:1 respectively. The compositions have increased shelf life and storage stability. The antimicrobial compositions can be formulated into a disinfection solution. Also provided are methods of disinfecting a surface that include applying the disinfecting solution to a surface, resulting in the destruction of a microbe on the surface.

Abstract: An oral rehydration composition comprising the following: 1-glutamic acid in a range of about 0.01% to about 0.40% w/w and monosodium glutamate in a range of about 0.05% to about 0.80% w/w; about 1.50% w/w glucose monohydrate; about 0.20% w/w sodium chloride; about 0.15% w/w potassium chloride; about 0.35% w/w glycine; about 0.30% w/w trisodiumcitrate; about 0.15% w/w sodium dihydrogen phosphate; about 0.10% w/w xanthan gum; 85% Steviol Glycoside extract in a range of about 0.01% to about 0.03% w/w; about 0.20% w/w citric acid monohydrate; hydrolyzed whey in a range of about 0.15% to about 1.00% w/w; about 1.00% w/w hydrolyzed wheat; comprises cereals as a protein source; comprises enzyme co-factors; comprises a monosaccharide. The oral rehydration composition can be used on humans or animals that suffer from diarrhea.

Abstract: A method of treatment of a neurodegenerative disease which is associated with a decline in mitochondrial activity, includes administering to a person in need of such treatment at least one of Glycolic acid or a pharmaceutically acceptable salt or ester thereof, and D-lactic acid or a pharmaceutically acceptable salt or ester thereof.

Abstract: Polyurea capsule compositions. A subset of these compositions contain a plurality of capsules and a capsule formation aid, in which each of the capsules contains a polyurea wall and an oil core; the polyurea wall is formed of a reaction product of a polyisocyanate and a cross-linking agent in the presence of the capsule formation aid; and the oil core contains an active material. The polyisocyanate, cross-linking agent, and capsule formation aids are described herein. Also disclosed are methods of preparing polyurea capsule compositions, as well as consumer products containing one of these compositions.

Abstract: The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine and one or more disinfectants, a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine, one or more disinfectants and one or more surfactants, a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine and one or more surfactants, a composition comprising, consisting essentially of, or consisting of one or more guanide-containing compound and one or more alcohols, kits comprising, consisting essentially of, or consisting of a disclosed composition, as well as methods and uses to clean, disinfect and/or sterilize a device using such compositions, methods and uses to clean, disinfect and/or sterilize a surface area using such compositions, methods and uses to clean, disinfect and/or sterilize a microbial infection in an individual using such composit

Abstract: In an example, a polymeric material includes a fibrous substrate, a cyclic compound chemically bonded to the fibrous substrate, and a microcapsule. The microcapsule has an encapsulated payload and is reversibly bonded to the fibrous substrate via the cyclic compound.

Abstract: In an example, a process for bonding a microcapsule having an encapsulating payload to a polymeric material. The process includes applying a microcapsule (having the encapsulated payload) that includes a dienophile functional group to a polymeric material that includes a diene functional group. The process further includes bonding the microcapsule having the encapsulated payload to the polymeric material via a chemical reaction of the dienophile functional group with the diene functional group.